Journal
Research notes & comparisons.
Practical guides to reconstitution math, ester kinetics, and side-by-side compound references — every article links back to the calculators and catalog.
Subscribe via RSSSARMs for Research: What the Science Class Actually Is (and Isn't)
A level-headed guide to selective androgen receptor modulators as research compounds — scaffold families, why 'selective' was the point, the mislabeling scandal that defines the market, and what legitimate SARM research looks like.
Read article
Semax vs Selank: Two Russian Heptapeptides, Two Research Lanes
ACTH-fragment lineage versus tuftsin lineage — how Semax and Selank differ in sequence origin, signaling focus (BDNF vs cytokine/GABA), and where each is used as a CNS reference peptide.
Read article
Testosterone Cypionate: The US Depot Standard, Examined
What testosterone cypionate is, why its ~8-day kinetics made it the pharmacy standard in the United States, and how it differs from enanthate beyond the ester.
Read article
The 2025-2026 US Peptide Market Collapse: What Fell, What Survived, and the New Bar for COAs
Nine+ US research-peptide vendors shut down between late 2025 and mid-2026 — Peptide Sciences overnight, Paradigm's founder to federal prison. The three enforcement forces behind the collapse, and the verifiable-COA standard that now separates survivors from the next casualty list.
Read article
BPC-157 and the 503A Bulks List: What the July 2026 FDA Recommendation Changes
BPC-157 was recommended for the FDA 503A Bulks List in July 2026 — what the vote means, what it doesn't change, and the research status of the pentadecapeptide.
Read article
GHK-Cu Reconstitution and Vial Math: 50 mg Copper Peptide in the Lab
GHK-Cu (CU50) vial math — reconstituting a 50 mg copper tripeptide vial, mg to mL conversions, and the concentrations used in cell-culture work.
Read article
The Peptide Cliff: Compounding Restrictions, the 503A Expansion, and What It Means for Research Supply
Why compounded semaglutide ended in 2025, what the July 2026 FDA 503A expansion changes, and how the regulatory shake-up reshapes the research peptide supply.
Read article
Tirzepatide Mechanism of Action: Dual GIP/GLP-1 Agonism in Research
How tirzepatide's dual GIP/GLP-1 receptor agonism and C20 fatty-diacid tail make it the reference 'twincretin' in metabolic research.
Read article
Retatrutide Research Findings: What the Trial Data and Preclinical Studies Show
The evidence base on retatrutide (LY3437943) — phase 2 dose-response data, the triple-agonist rationale, and what the findings mean for metabolic research.
Read article
Semaglutide Mechanism of Action: GLP-1 Receptor Agonism in Research
How semaglutide's GLP-1 receptor agonism, Aib-8 stabilization and C18 fatty-acid chain make it the reference standard for GLP-1 research.
Read article
Semaglutide vs Retatrutide: GLP-1 Selective vs Triple Agonist
Selective GLP-1 agonism versus triple GIP/GLP-1/glucagon agonism — how semaglutide and retatrutide differ in mechanism, molecular size and research use.
Read article
TB-500 Mechanism of Action: The Thymosin Beta-4 Fragment and Actin Binding
How TB-500's conserved actin-binding (LKKTETQ) domain drives the cell-migration and tissue-repair mechanisms studied in research.
Read article
TB-500 Dosage and Reconstitution Math: 5 mg Vial in the Lab
TB-500 vial math — reconstituting a 5 mg thymosin beta-4 fragment vial, mg to mL and U-100 unit conversions, and common research dose ranges.
Read article